AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 183 min read$TNXP

Tonix Pharmaceuticals Holding Corp. (TNXP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Interim Chief Medical Officer On August 18, 2026, the Board of Directors of Tonix Pharmaceuticals Holding Corp. (the “Compa

Original reporting
SEC EDGAR 8-K
Published Aug 18, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$TNXP
Neutral
medium confidence
Mentioned
$TNXP
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TNXPNeutralLow
01

Why it matters

Appointing the CEO as Interim Chief Medical Officer can streamline decision-making, but the disclosure lacks any accompanying clinical data, trial timeline changes, or funding updates.

02

Market read

This is a governance and officer-appointment update with no new clinical or financial datapoints, so trading impact is likely limited.

03

What to watch

Traders should watch for subsequent 8-Ks or press releases that pair the leadership change with specific clinical trial readouts, protocol amendments, or regulatory interactions.

Relevance 6/10Novelty 4/10Timing: filed Aug. 18, 2026, after-hours/late session disclosure

Background

Tonix filed an SEC Form 8-K (Item 5.02) announcing an interim medical leadership appointment.

Company-level read

Ticker impact

$TNXPNeutralMedium confidence
Context

Tonix appointed its CEO, Dr. Seth Lederman, as Interim Chief Medical Officer via an Item 5.02 8-K filed Aug. 18, 2026.

Expected impact

Likely modest, sentiment-driven reaction rather than a fundamental repricing absent accompanying trial or regulatory updates.

Evidence & confidence

This is a corporate governance/officer appointment disclosure. The 8-K states the CEO will serve as Interim CMO and includes no new trial results, guidance, or regulatory decisions.

Market effects

Sector

Limited read-through to biotech sector beyond potential emphasis on clinical leadership continuity.

Regional

No clear regional spillover indicated by the filing.

Global

Primarily company-specific governance news with no stated international operational change.

Counterpoint

What could challenge this read

The interim CMO appointment may reflect internal staffing gaps rather than a strategic upgrade, so the market could discount it if no clinical milestones follow.

Key entities

  • company
    Tonix Pharmaceuticals Holding Corp.

    NASDAQ-listed biotech that appointed its CEO as Interim Chief Medical Officer.

  • person
    Dr. Seth Lederman

    President, CEO, and Chairman since October 2011, appointed Interim Chief Medical Officer on Aug. 18, 2026.

Read at source← All news

Related articles

AUG 24
$TNXPLow

Next-Generation Mpox Vaccine Shows Promise for Durable Protection and Future Outbreak Preparedness

Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin

infectioncontroltoday.com3 min
AUG 17
$TNXPMedAI 8/10

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.

fool.com6 min
AUG 10
$TNXPMedAI 8/10

Tonix Pharmaceuticals Holding Corp. (TNXP): Results of Operations and Financial Condition

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.01 Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, no

SEC EDGAR 8-K7 min
AUG 10
$TNXPMedAI 8/10

Tonix's Fibromyalgia Treatment Reaches 136M Covered Lives

Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q2 2026 net product revenue of about $13.5M, up from $2.0M a year earlier, driven by TONMYA sales of about $11.0M and migraine products Zembrace SymTouch and Tosymra. TONMYA prescriptions rose to 12,592 and coverage expanded to ~136M lives. Cash was ~$176.2M at June 30, 2026; net loss was $40.6M.

stocktitan.net6 min